Danaher (DHR) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 9.62%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.57 per share when it actually produced earnings of $1.72, delivering a surprise of 9.55%. Over the last four quar ...

WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71. Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%. Ope ...

Exhibit 99.1 Innovation at the speed of life Danaher Reports Third Quarter 2024 Results WASHINGTON D.C., October 22, 2024 -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results • Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71. • Revenues incr ...

Core Insights - Danaher (DHR) is expected to report quarterly earnings of $1.56 per share, reflecting a year-over-year decline of 22.8% [1] - Revenue projections stand at $5.59 billion, down 18.6% from the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analyst forecasts [1] Sales Estimates - The consensus estimate for 'Total sales- Diagnostics' is $2.19 billion, representing a decrease of 2.6% from the prior year [2] - 'Total sales- Life Sciences' is projected to be $1.77 billion, indicating an increase of 4% year-over-year [2] - 'Total sales- Biotechnology' is expected to reach $1.61 billion, reflecting a decline of 3.1% from the previous year [2] Operating Profit Estimates - Analysts forecast 'Operating profit- Life Sciences' at $252.85 million, down from $313 million in the same quarter last year [3] - 'Operating profit- Biotechnology' is estimated at $392.48 million, compared to $417 million a year ago [3] - The estimated 'Operating profit- Diagnostics' is $524.51 million, down from $539 million in the prior year [3] Stock Performance - Over the past month, Danaher's shares have returned -1.4%, while the Zacks S&P 500 composite has increased by 3.8% [3] - Danaher currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [3]

Danaher Corporation (DHR) is poised to benefit from strength in its clinical diagnostics business, backed by growth in Leica Biosystems and Beckman Colter Diagnostics units. The company has been witnessing positive responses for its new products like Aperio GT 450 DX and Access NT ProBNP, both of which received the FDA 510K clearance. Also, higher demand for respiratory and non-respiratory disease tests augers well for DHR’s molecular diagnostics business.The company believes in expanding its market presenc ...

I reiterated my ‘Strong Buy’ rating for Danaher (NYSE: DHR ) in my previous article published in April 2024, pointing out Danaher’s worst time has already passed. The company’s Q2 result on July 23 demonstrated furtherMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a solid management team, a ...

Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Automated and Closed Cell Therapy Market 2024-2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the global market for automated and closed cell therapy was valued at $1.5 billion. The market is forecast to grow at a CAGR of 23.9% to reach $5.3 billion at the end of 2029. The report highlights the current and future market potential of automated and closed cell therapy systems and a detailed analysis of the market drivers, restr ...

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheadin ...

BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. Scopio's X100 / X100HT with FF-BMA Application are CE-Marked. Bone marrow aspirate analysis is a vital procedure providing essential ...

WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of t ...